Tirzepatide (Mounjaro, Zepbound): Two Receptors, Unequally Engaged

The short version

The gut releases more than one hormone after a meal. Two of them — GLP-1 and GIP — both tell the pancreas to release insulin. For thirty years the drug industry chased the first and largely ignored the second.

Tirzepatide (Mounjaro, Zepbound) is a single molecule that switches on both. It is one chain of 39 amino acids, engineered from the GIP hormone rather than the GLP-1 one, with a fatty-acid arm attached so it survives a full week in the bloodstream. The two brand names hold the same peptide; they mark different approved uses, not different drugs.

Engaging both receptors turns out to do more than engaging one. It increases insulin release, suppresses the hormone that raises blood sugar, slows the stomach, and reduces appetite — and in trials it produced larger weight and blood-sugar effects than a GLP-1-only drug did.

It is the lead compound on this desk for two reasons. It is the first dual agonist any regulator approved, and it is the only compound here that has beaten the class benchmark in a direct comparison rather than against a placebo.

It is an approved prescription medicine. This page reports research; it does not recommend anything.

What it is

Tirzepatide is a linear 39-amino-acid synthetic peptide built on the native GIP sequence, with a C20 fatty diacid — eicosanedioic acid — attached to a lysine side chain through a glutamic acid linker and two (2-(2-aminoethoxy)ethoxy)acetic acid units. Molecular formula C225H348N48O68.

The fatty-diacid arm is the same design principle used elsewhere in this class: it confers high albumin affinity, extends the half-life, and makes once-weekly administration viable.

Its formal class is dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The informal name that stuck in the literature is twincretin.

A peer-reviewed clinical-reference chapter confirms it as an approved dual agonist of the GLP-1 and GIP receptors, first cleared in May 2022 for type 2 diabetes mellitus, and notes that at the time of writing weight-loss use was off-label and that the agent is not approved for type 1 diabetes ^[6]. Subsequent approvals extended it to chronic weight management in adults with obesity, or overweight with a weight-related condition, and to moderate-to-severe obstructive sleep apnoea in adults with obesity. All approved formulations are prescription-only.

Those indications are split across two brand names. The type 2 diabetes product is marketed as Mounjaro; the chronic weight management and obstructive sleep apnoea product is marketed as Zepbound. Same 39-amino-acid peptide, same mechanism, same trial programme behind it — the split is regulatory and commercial rather than pharmacological, which is why a reader comparing the two products will find no difference in the science on this page. The trials below are reported under the drug name, as their investigators reported them.

How it works

The one-line version — dual agonism produces larger effects than single agonism — is true but hides the more interesting finding, which is that the two arms are not pulled equally.

In vitro receptor-occupancy and signalling work established that tirzepatide is an imbalanced dual agonist: it engages the GIP receptor to a greater degree than the GLP-1 receptor. At the GLP-1 receptor it also shows biased signalling, favouring cAMP generation over beta-arrestin recruitment, with weaker receptor internalisation than native GLP-1 produces ^[10].

That bias is not a curiosity. Beta-arrestin recruitment is one of the mechanisms by which a receptor is desensitised and pulled off the cell surface. In primary islet experiments, beta-arrestin1 limited the insulin response to GLP-1 but did not limit the response to GIP or to tirzepatide ^[10]. The proposed consequence is a more sustained insulin-secretory signal than a conventional, unbiased GLP-1 agonist can maintain.

The discovery and proof-of-concept programme laid the physiological groundwork. The molecule activated both receptor pathways in vitro and improved glucose-dependent insulin secretion and glucose tolerance in mice; with chronic administration in mice it decreased body weight and food intake significantly more than a selective GLP-1 receptor agonist did. A phase 1 programme comprising single- and multiple-ascending-dose studies in healthy volunteers plus a four-week phase 1b proof-of-concept study in type 2 diabetes — 142 subjects dosed in total — supported once-weekly administration and showed reduced fasting glucose and body weight against placebo ^[11].

Downstream, the combined effect is conventional incretin physiology amplified: enhanced glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and reduced appetite and food intake.

Mechanistic targets: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R).

What the trials show

The clinical programme splits into obesity trials (SURMOUNT) and diabetes trials (SURPASS), with one direct comparison against the class benchmark.

SURMOUNT-1 — obesity, against placebo. A 72-week phase 3 double-blind randomised trial in 2,539 adults with obesity (body-mass index 30 or above, or 27 or above with a weight-related complication) and without diabetes. Mean weight change at week 72 was -15.0%, -19.5% and -20.9% in the 5 mg, 10 mg and 15 mg study arms respectively, against -3.1% on placebo. The most common adverse events were gastrointestinal, mostly mild to moderate, and occurred primarily during dose escalation ^[8].

SURMOUNT-5 — obesity, head to head. A phase 3b open-label trial randomised 751 adults with obesity and without type 2 diabetes to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of semaglutide (1.7 or 2.4 mg), once weekly for 72 weeks. Least-squares mean weight change at week 72 was -20.2% with tirzepatide against -13.7% with semaglutide (P<0.001). Tirzepatide also produced a greater reduction in waist circumference and higher proportions of participants reaching 10%, 15%, 20% and 25% weight loss thresholds ^[1].

SURPASS-2 — type 2 diabetes, head to head. An open-label 40-week phase 3 trial in 1,879 adults with type 2 diabetes. Once-weekly tirzepatide at 5, 10 and 15 mg reduced glycated haemoglobin by an estimated 2.01, 2.24 and 2.30 percentage points respectively, against 1.86 percentage points with semaglutide 1 mg — non-inferior at all doses and superior at all doses. Weight reductions were also greater, with treatment differences of -1.9 kg, -3.6 kg and -5.5 kg. Adverse events were again predominantly gastrointestinal and mostly mild to moderate ^[9].

Targeted safety analysis. A systematic review and meta-analysis of nine randomised controlled trials totalling 9,871 participants examined two specific signals against controls (basal insulin, selective GLP-1 receptor agonists, or placebo). Pancreatitis was not significantly increased (relative risk 1.46, 95% CI 0.59–3.61). The composite of gallbladder or biliary disease was significantly increased (relative risk 1.97, 95% CI 1.14–3.42), although no individual component — cholelithiasis, cholecystitis, or biliary disease alone — reached significance ^[7].

One provenance note belongs alongside these numbers: the highest-quality efficacy evidence here is sponsor-funded manufacturer-run phase 3 work. That is standard for a novel drug, and it is stated rather than omitted.

What to watch: reported effects and cited cautions

Two classes of information follow, and the distinction between them is the point of this section.

Community reports — anecdotal, not clinical evidence

What follows is drawn from patient communities, published exit-interview accounts and post-marketing discussion. It is anecdotal, not clinical evidence: uncontrolled, self-selected and unverified. Frequencies below are described in words rather than numbers because the underlying reports are not audited data. No dose accompanies any of it.

Reported as beneficial. Appetite suppression is described more consistently than anything else — the quieting of intrusive food-related thought, the mental loop of meal planning and snack anticipation going silent. Many describe simply forgetting to eat because the drive to seek food faded. Increased energy and reduced sluggishness as weight declines are commonly described, though early fatigue in the first weeks while intake drops is also reported. Improved mood, confidence and emotional well-being come up frequently in structured interview accounts, with a minority reporting no psychological change despite substantial weight loss. Better sleep, reduced snoring and reduced sleep-apnoea symptoms are described by some, as is reduced joint pain and easier movement in those who have lost a large amount of weight. Improved self-monitored glucose, cholesterol and triglyceride readings are also a recurring theme.

Reported as adverse. Nausea is the most commonly reported problem, typically peaking in the first week or two of a new amount and again after each step up, and usually fading within a few weeks. An alternating pattern of constipation and loose stools is frequently described and is attributed by those reporting it to slowed gastric emptying. Sulfur-smelling burps are reported by a subset. Injection-site reactions — redness, itching, tenderness, occasional bruising or small lumps — are among the most reported categories in post-marketing data, generally appearing within hours and resolving in a few days. Metallic or altered taste and previously enjoyed foods becoming off-putting are described by some and are not listed as common in prescribing information. Weight-loss plateaus are widely discussed and are characterised by clinicians as a normal part of the arc rather than treatment failure. Concern about losing muscle alongside fat is common among those who train, with community discussion focused on protein intake and resistance work. Hair thinning appearing a few months in is reported by a subset and is attributed to the speed of weight loss rather than the drug.

Cited cautions from the clinical literature

• Gastrointestinal intolerance during dose escalation. Dose-dependent nausea, vomiting, diarrhoea, constipation and decreased appetite are by far the most common adverse effects, emerging chiefly during the stepwise increase and generally easing with continued exposure. In the pivotal obesity trial they were mostly mild to moderate and concentrated in the escalation period ^[8]; the diabetes programme reported the same pattern ^[9]. They drive the bulk of discontinuations.
• Thyroid C-cell tumours, medullary thyroid carcinoma and MEN-2 (boxed warning). The prescribing information carries a boxed warning derived from rodent studies in which the structurally related incretin class caused dose- and duration-dependent thyroid C-cell tumours. Whether this translates to humans is not established. The label states the drug should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 ^[6]. This is a label-mandated contraindication grounded in animal data, not a confirmed human outcome.
• Pancreatitis. A recognised class concern, monitored on the label and captured in post-marketing reporting. The dedicated meta-analysis of nine randomised trials found no statistically significant increase against controls (relative risk 1.46, 95% CI 0.59–3.61) ^[7]. The signal is monitored and label-flagged rather than confirmed at trial level; severe, persistent abdominal pain remains a reason to seek clinical assessment.
• Gallbladder and biliary disease. The same meta-analysis found a significantly increased risk of the gallbladder-or-biliary composite (relative risk 1.97, 95% CI 1.14–3.42) ^[7]. Rapid weight loss is a known precipitant of gallstones, which fits the mechanism.
• Hypoglycaemia when combined with insulin or sulfonylureas. Alone, the compound stimulates insulin secretion in a glucose-dependent fashion, so hypoglycaemia risk is low. Added to a sulfonylurea or insulin, that changes, and the label advises that a lower dose of the concomitant secretagogue or insulin may be needed.
• Delayed gastric emptying and perioperative aspiration risk. The compound transiently delays gastric emptying, an effect that attenuates with continued dosing. Retained gastric contents have been observed at upper-gastrointestinal endoscopy and are a theoretical concern for pulmonary aspiration under sedation or general anaesthesia, though documented aspiration is rare. Prolonged fasting, point-of-care gastric ultrasound and prokinetics around procedures have all been proposed.
• Lean-mass and skeletal-muscle loss. As with potent incretin therapies generally, a meaningful fraction of the weight lost is lean mass rather than fat. Body-composition substudies and systematic reviews across the class have quantified this, and resistance exercise has been recommended to help preserve muscle. The functional significance is still being defined, and few studies have measured objective physical function.
• Dehydration and acute kidney injury from gastrointestinal fluid losses. Severe or prolonged vomiting and diarrhoea with reduced fluid intake can cause volume depletion, the proposed mechanism by which incretin therapies could precipitate acute kidney injury — particularly in people already dehydrated or taking diuretics, ACE inhibitors or angiotensin-receptor blockers. Large randomised and observational datasets do not show a significant increase in acute kidney injury risk, and may suggest renal benefit in high-risk groups. The risk tracks the severity of gastrointestinal effects rather than the drug itself.
• Reduced oral-contraceptive reliability. Because gastric emptying is slowed, absorption of co-administered oral medicines can be altered, and the prescribing information advises that the effectiveness of oral hormonal contraceptives may be reduced — especially around the initial dose and each increase, when the effect is greatest. A non-oral or barrier method is the label-suggested mitigation during that window.
• Weight regain after stopping. Pooled withdrawal data show substantial regain proportional to the amount initially lost, with regain tracking worsening cardiometabolic risk factors. A randomised withdrawal trial showed participants switched to placebo regained weight while those continuing kept losing. This is chronic rather than short-course therapy.
• A tolerability–efficacy trade-off. Overall and serious adverse-event rates are broadly similar to comparator incretins, but discontinuation due to adverse events is higher, driven largely by gastrointestinal effects. Post-marketing series have also flagged incorrect dose administration as a frequently reported event, which underscores that this is a drug requiring clinical supervision of titration and technique.
• Hair loss during rapid weight reduction. Reversible diffuse shedding has been reported, attributed largely to the physiological stress of rapid weight loss and reduced nutrient intake rather than direct drug toxicity, and typically self-limiting once weight stabilises.

What remains unknown

Three questions sit open on the current record.

How much of the advantage comes from the GIP arm. The head-to-head results ^[1][9] establish that the dual agonist outperforms the single one, but not why. The imbalanced, GIPR-favouring engagement and the biased GLP-1 receptor signalling are both plausible explanations ^[10], and the two are not mutually exclusive. Attributing the clinical margin to one mechanism is not yet possible.

What the lean-mass loss actually costs. The body-composition finding is well documented across the class. Whether it produces measurable decline in strength, mobility or function — and in whom, and over what horizon — is not. Few studies have measured objective physical function at all.

What happens over decades. Weight regain on discontinuation frames this as continuous therapy, but the trial record is measured in months and a small number of years. Long-horizon safety, and whether the boxed-warning thyroid signal ever materialises in humans, will be answered by pharmacovigilance rather than by any trial now running ^[6].

A fourth item is not a scientific unknown but a supply one: compounded versions proliferated during a documented shortage period, and regulators have raised concerns about the quality, purity and identity of non-approved compounded sources. No efficacy or safety figure on this page transfers to material of unverified identity.

Where it fits in metabolic research

Tirzepatide is the proof that the incretin field had been leaving something on the table. GIP was the neglected half of the incretin effect for decades; adding it to GLP-1 in a single molecule produced a step change in both glycaemic and weight outcomes ^[1][8][9].

Against semaglutide, it wins on weight and on glycaemia in the trials that compared them directly, while inheriting the same class-level cautions almost unchanged — gastrointestinal intolerance, the boxed thyroid warning, biliary disease, lean-mass loss, regain on stopping. Greater potency has not bought a cleaner safety profile; it has bought a larger effect with the same profile and a somewhat higher discontinuation rate.

Against retatrutide, the comparison is not yet available. Retatrutide's phase 2 weight figures exceed tirzepatide's phase 3 ones ^[15], but placebo-controlled phase 2 numbers and head-to-head phase 3 numbers are different currencies, and no trial has yet spent the second.

Tesamorelin is not a competitor at all — different receptor, different axis, different endpoint. It appears on this desk because it answers a related question by a completely different route. The comparison page works through all four.